Phesi Inc. and Accenture have released the first of a series of reports exploring the use of synthetic data in clinical development. In recent years, the volume of data created through clinical trials and electronic patient records has increased exponentially, as well as the ability to process and analyze these data. The report outlines several advantages of synthetic data.
The report outlines two cases where use of synthetic data made significant improvements to the trial process: oncology and gastroenterology. In oncology, trials are often extremely costly and time-intensive; a study has recently shown that without a synthetic control arm, the median R&D cost for oncology drugs is $2.77 billion, which is driven by the high failure rate of up to 80%. Recruiting patients in a timely manner is also a challenge in oncology, resulting in a lag in getting treatments to market. The use of synthetic data can help to overcome these challenges by reducing patient numbers and eliminating placebos, helping to speed up the process. In ulcerative colitis, synthetic patient data can be used to synthesize baseline patient characteristics to optimize the protocol design and to again reduce patient numbers and exposure to a comparator.
For more of the report’s findings, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.